证券代码：600873 证券简称：梅花生物 公告编号：2025-059 梅花生物科技集团股份有限公司 第十届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、会议召开情况 梅花生物科技集团股份有限公司（以下简称"公司"）第十届董事会第二十 三次会议于 2025 年 12 月 11 日以现场和通讯相结合的方式召开，会议应出席董 事 5 人，实际出席董事 5 人，会议由董事长王爱军女士主持，公司监事和部分高 级管理人员列席了会议。本次会议的召集、召开符合《公司法》和《公司章程》 的规定。 二、会议审议情况 经出席本次会议的全体董事审议，以投票表决方式通过以下议案： 1.关于变更注册资本的议案 根据 2024 年第二次临时股东大会审议通过的《关于以集中竞价交易方式回 购公司股份的议案》，回购的股份全部用于注销，减少公司注册资本。公司已完 成该次回购，已实际回购股份 48,547,100 股，该部分股份注销完成后，公司注册 资本由 2,852,788,750 元变更为 2,804,241,650 ...

2、2026 年员工持股计划（草案）已通过公司职工代表大会充分征求了员工 意见，拟参与对象遵循依法合规、自愿参与、风险自担的原则，不存在以摊派、 强行分配等方式强制员工参与员工持股计划的情形。 3、公司实施 2026 年员工持股计划有利于进一步完善公司法人治理结构，建 立员工、公司、股东风险共担、利益共享机制，吸引和保留优秀管理人才和业务 骨干，有效调动管理和技术人员的积极性，促进公司长期、持续、健康发展，不 会损害公司及全体股东的利益，符合公司长远发展的需要。 综上，我们同意公司实施 2026 年员工持股计划（草案），并将 2026 年员工 持股计划（草案）及其相关议案提交公司董事会审议。 梅花生物科技集团股份有限公司 董事会薪酬与考核委员会 关于公司 2026 年员工持股计划相关事项的核查意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）《关于上市公司实 施员工持股计划试点的指导意见》（以下简称"《指导意见》"）《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》（以下简称"《自律监管指引》"）等 相关法律、法规及规范性文件的规定，我们作为梅花生物科技集团股份有限公司 （以下简称"公司 ...

截至发稿，梅花生物市值为279亿元。 每经头条（nbdtoutiao）——专访管涛：美国政府经济贸易政策正逐渐动摇美元本位国际货币体系，利 多因素下人民币汇率有可能破7 每经AI快讯，梅花生物（SH 600873，收盘价：9.95元）12月11日晚间发布公告称，公司第十届第二十 三次董事会会议于2025年12月11日以现场和通讯相结合的方式召开。会议审议了《关于变更注册资本的 议案》等文件。 2024年1至12月份，梅花生物的营业收入构成为：生物发酵占比97.34%，医药健康占比1.9%，其他业务 占比0.76%。 （记者 王晓波） ...

梅花生物（600873）(600873.SH)发布2026年员工持股计划(草案)，员工持股计划设立时计划份额合计不 超过15,000万份，以"份"为认购单位，每1份额的认购价格为人民币1.00元，筹集资金总额上限为15,000 万元。参加员工持股计划的总人数不超过300人，持股计划的存续期为60个月，自公司公告最后一笔标 的股票过户至本员工持股计划名下之日起算。本员工持股计划所获标的股票自公司公告最后一笔标的股 票过户至本员工持股计划名下之日起满12个月、24个月后分两期解锁，最长锁定期为24个月，每期解锁 的标的股票比例分别为50%、50%。 ...

Core Viewpoint - The production of monosodium glutamate (MSG) in China is experiencing stable growth, with a projected output of 3.015 million tons in 2024, representing a year-on-year increase of 11.9% [1][10]. Industry Overview - MSG is primarily composed of sodium glutamate, produced through fermentation of starch or sugar by microorganisms, resulting in a product with a sodium glutamate content of 99% or higher [2][4]. - The demand for MSG is driven by the increasing quality and taste expectations of consumers, particularly in the food service and processed food sectors [1][10]. Market Demand - The apparent consumption of MSG in China is expected to reach 2.997 million tons in 2024, marking a 12.0% increase year-on-year [1][10]. - The food processing industry is the largest consumer of MSG, accounting for over 50% of the market, followed by the restaurant sector at approximately 30% [8][9]. Production and Export - China's MSG production capacity utilization rate is projected to be 84.7% in 2024 [1][10]. - In the first nine months of 2025, China exported 6,700 tons of MSG, generating an export revenue of approximately $8.72 million [1][11]. Competitive Landscape - The MSG market in China is characterized by a duopoly led by two major players: Fujian Fengfeng Group and Meihua Biological Technology Group, which dominate the industry with their extensive product offerings and global reach [11][12]. - Fujian Fengfeng Group reported a revenue of 13.96 billion yuan and a gross profit of 3.169 billion yuan in the first half of 2025, with a gross margin of 22.7% [12]. - Meihua Biological Technology Group achieved a revenue of 12.28 billion yuan in the same period, with a significant portion derived from feed amino acids and flavoring agents [12][13]. Future Trends - The MSG industry is expected to evolve towards low-sodium, natural fermentation, and composite flavor products, with a focus on customized solutions for the food processing and restaurant sectors [14]. - The growth in demand for specialized formulations for baking, pre-prepared dishes, and hot pot bases is anticipated to drive innovation and differentiation in the market [14].

Group 1 - The average price of live pigs in China is 11.63 yuan/kg as of November 29, showing a decline of 1.11% compared to the previous weekend, with the industry facing a loss of 111 yuan per head for nine consecutive weeks [1] - The price of weaned piglets at 7 kg is 209 yuan per head, with an average loss of approximately 81 yuan per head for exported piglets this week [1] - The average slaughter weight this week is 129.22 kg, with a slight increase of 0.41 kg week-on-week, while the average slaughter weight for smallholders is at a high of 145.17 kg [1] Group 2 - The demand side shows an increase in daily slaughter volume by 3.39% week-on-week, driven by northern slaughterhouses responding to low pig prices and the onset of seasonal consumption in southern markets [1] - There are sporadic outbreaks of pig diseases in certain regions due to cooler weather, with the proportion of pigs under 90 kg in total slaughter increasing to 4.83%, up by 0.34% from last week [1] - The agricultural team emphasizes the importance of monitoring the pig sector's capacity reduction due to production cuts, losses in farming, and disease interference, suggesting that capacity may continue to decrease [1] Group 3 - As of December 3, 2025, the CSI Livestock Breeding Index shows significant gains for several stocks, including Luoniushan up by 9.98% and Yike Foods up by 3.36% [2] - The Livestock ETF closely tracks the CSI Livestock Breeding Index, which includes companies involved in feed, veterinary drugs, and livestock farming [2] - The top ten weighted stocks in the CSI Livestock Breeding Index account for 65.6% of the index, with major companies like Muyuan Foods and Wens Foodstuffs leading the list [2]

近日，梅花生物发布公告称，收到了广东高院受理的由日本味之素株式会社（以下简称"味之素"）提起的侵害专利权的《民事起诉状》等文件。 截至公告发布日，上述诉讼案件尚未公开审理。梅花生物称诉讼结果存在不确定性，暂无法判断是否会对公司损益产生影响。 三季报显示，梅花生物前三季度实现营业收入182.15亿元，同比减少2.49%；实现净利润30.25亿元，同比增长51.61%。其中，第三季度实现营业收入59.35亿 元，同比减少1.71%；实现净利润12.57亿元，同比增长141.06%。 味之素认为梅花生物及其子公司通辽梅花、新疆梅花、吉林梅花在味精的生产、销售过程中，侵犯了其200580045189.5号、201480005332.7号专利权，所以 向广东高院提起诉讼。要求梅花生物及其子公司立即停止侵犯上述专利权的制造、销售、使用、许诺销售侵权行为，并销毁专用于生产被控侵权产品的设 备，以及销毁所有库存侵权产品，同时赔偿侵犯两项专利造成的经济损失共计2.6亿元。 梅花生物则在公告中提到，其与味之素为长期合作伙伴，在知识产权领域包括味精的生产技术领域有着多项合作共识，且其他多项合作至今仍然存续。 ...

Investment Rating - The report maintains a "Recommended" rating for the chemical industry [1] Core Insights - The chemical industry is expected to benefit from a shift in supply chain dynamics due to geopolitical tensions, particularly in semiconductor materials, leading to accelerated domestic replacements [5][6] - The chromium salt industry is experiencing a value reassessment driven by increased demand from AI data centers and commercial aircraft engines, with significant price increases noted [8][9] - The report highlights a potential upturn in the chemical industry as supply-side constraints and rising demand could enhance profitability and dividend yields for leading companies [6][10] Summary by Sections Industry Performance - The basic chemical sector has shown a 24.0% increase over the past 12 months, outperforming the CSI 300 index, which increased by 16.9% [3] Key Opportunities - Focus on low-cost expansion opportunities in companies such as Wanhua Chemical and Hualu Hengsheng, as well as sectors like tire manufacturing and pesticide formulations [6][9] - Emphasis on sectors with improving market conditions, including chromium salts, phosphate rock, and polyester filament [9][10] Price Trends - Recent price increases for key products include chromium oxide green at 35,500 CNY/ton and metallic chromium at 84,000 CNY/ton, both up by 1,000 CNY/ton from the previous week [8][16] - The report notes a tightening supply for isooctanol, with prices rising due to increased demand and production disruptions [13] Company Focus - The report identifies several key companies for investment, including Dongfang Shenghong, Hubei Yihua, and Wanhua Chemical, with positive earnings forecasts and attractive price-to-earnings ratios [28]

Core Viewpoint - Meihua Biological and its subsidiaries are facing a lawsuit from Ajinomoto Co., Inc. for patent infringement, with potential damages amounting to 260 million yuan [2][3] - The company is also dealing with internal issues, including the imprisonment of its controlling shareholder Meng Qingshan for market manipulation, which raises concerns about governance and operational stability [5][6][7] - Despite recent operational challenges, the company has shown signs of recovery in its financial performance, although long-term revenue growth remains a concern [8][9] Legal Issues - Meihua Biological received a civil lawsuit from Ajinomoto, claiming infringement of two patents related to the production of monosodium glutamate, seeking 260 million yuan in damages [3] - Ajinomoto holds two patents: one for "Microorganisms producing L-glutamic acid" and another for "Manufacturing methods of L-amino acids" [3] - The company asserts its commitment to intellectual property rights and plans to actively defend against the lawsuit [4] Management and Governance - Meng Qingshan, the controlling shareholder, was sentenced to three years in prison (with a five-year probation) for manipulating the securities market, which raises governance concerns [5][6] - The company emphasizes that Meng has not held any position since his retirement in 2017 and that his legal issues do not impact the company's operations [7] Financial Performance - Meihua Biological experienced revenue declines in 2023 and 2024, with revenues of 27.761 billion yuan and 25.069 billion yuan, representing decreases of 0.63% and 9.69% year-on-year, respectively [8] - Net profits also fell during this period, with a decline of 27.81% and 13.85% [8] - In the first half of 2025, the company reported a revenue of 12.28 billion yuan, down 2.87%, but net profit increased by 19.96% to 1.768 billion yuan, attributed to improved sales and reduced raw material costs [8][9] Future Outlook - Despite recent improvements in profitability, industry experts caution that the company faces a "profit increase without revenue increase" situation, indicating potential long-term revenue growth challenges [9] - Meihua Biological is actively pursuing overseas acquisitions to enhance its growth prospects, with a focus on integrating these assets to drive revenue and profit growth [9]

Core Viewpoint - Meihua Biological is facing significant legal and operational challenges, including a lawsuit from Ajinomoto Co., Inc. for patent infringement with a claim of 260 million yuan, and the imprisonment of its controlling shareholder for market manipulation, which raises concerns about the company's long-term growth potential despite recent improvements in profitability [1][4][7]. Legal Issues - Meihua Biological has been sued by Ajinomoto for allegedly infringing on two patents related to the production of monosodium glutamate, with a total compensation claim of 260 million yuan [2][3]. - Ajinomoto claims ownership of two patents: one for "microorganisms producing L-glutamic acid" and another for "methods for producing L-amino acids" [2]. - Meihua Biological asserts that it has a long-standing partnership with Ajinomoto and respects intellectual property rights, indicating ongoing collaborations in technology [3]. Management and Governance - The controlling shareholder, Meng Qingshan, was sentenced to three years in prison (with a five-year probation) for manipulating the securities market, which has raised governance concerns [4][5]. - Meng Qingshan's actions were linked to a non-public offering in 2013, where he manipulated stock prices to avoid losses related to trust agreements [4][5]. - Following his retirement in 2017, Meng no longer holds any position in the company, and Meihua Biological claims that his legal issues do not affect the company's operations [6]. Financial Performance - Meihua Biological's revenue and profit have experienced fluctuations, with revenues of 27.76 billion yuan and 25.07 billion yuan in 2023 and 2024, respectively, reflecting declines of 0.63% and 9.69% year-on-year [7]. - Despite a revenue decline in the first half of 2025, net profit increased by 19.96% to 1.768 billion yuan, attributed to improved sales of key products and reduced raw material costs [7]. - The company's third-quarter report for 2025 showed a slight revenue decrease of 2.49% but a significant net profit increase of 51.61%, reaching 3.025 billion yuan, driven by cost advantages and overseas acquisitions [8]. Industry Outlook - While recent profitability improvements are noted, industry experts caution that the company faces a "profit increase without revenue growth" scenario, indicating potential long-term revenue growth challenges [8]. - Meihua Biological is actively pursuing overseas acquisitions, such as the purchase of a major Japanese amino acid company, to enhance its global presence and drive future growth [8].